Sabby Management’s ADMA Biologics ADMA Stock Holding History

Sabby Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-100,000	Closed	-$595K	–	312
2016 Q2	$595K	Buy	+100,000	New	+$700K	0.03%	203

Other funds holding ADMA

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WMSA

Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

Sabby Management's ADMA Position: Q3 2016 in Review

Sabby Management sold out of ADMA Biologics (ADMA) in Q3 2016, closing a stake of 100,000 shares — an estimated $595K sold.

Sabby Management first reported a position in ADMA in Q2 2016 and held it in 1 quarter. The position peaked at $595K in Q2 2016. 19 funds tracked by Wall St. Rank hold ADMA as of Q3 2016.

Sabby Management reported no remaining ADMA Biologics position as of Q3 2016 after selling out during the quarter.
Sabby Management sold 100,000 ADMA Biologics shares in Q3 2016, an estimated $595K.
Sabby Management first reported a position in ADMA Biologics in Q2 2016 and held it in 1 quarter.
Sabby Management's ADMA Biologics position peaked at $595K in Q2 2016.
19 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.